Pharmacogenetics study of anti-parkinson's disease drug levodopa

• Register: ChiCTR
• Last refreshed on: 18 April 2017
• Main ID: ChiCTR-OCS-12002720
• Date of registration: 2012-11-26
• Prospective Registration: No
• Primary sponsor: Institute of Clinical Pharmacology, Central South University
• Public title: Pharmacogenetics study of anti-parkinson's disease drug levodopa
• Scientific title: The association between polymorphisms of DRD2, DRD2, SLC6A3 and the levodopa response
• Date of first enrolment: 2012-09-01
• Target sample size: A:200;
• Recruitment status: Completed
• URL: http://www.chictr.org.cn/showproj.aspx?proj=6834
• Study type: Observational study
• Study design: Cross-sectional
• Phase: Post-market

Contacts

• Name: Huizi Wu
• Affiliation: Institute of Clinical Pharmacology, Central South University

• Name: JieLiu, Huizi Wu

Key inclusion & exclusion criteria

Inclusion criteria: 1. Parkinson's disease patients with motor symptoms include shaking, rigidity, slowness of movement and difficulty with walking and gait;
2. Patients two major motor symptoms as follow: static tremor, slowness of movement, Gear myotonia, and Posture reflex disorder;
3. Have response to levodopa;
4. with no other Parkinson-like syndrome or disease.
Exclusion criteria: 1. Patient's sydrome was not root from cerebral trauma,cerebrovascular disease, brain tumor, virus infection or other nervous system disease;
2.Patients should not have gastrointestinal disorders or other disease;
3.Patients should not with heavy drinking and smoking or use other kind of CNS drugs.

Age minimum: 38
Age maximum: 72
Gender: Both

Health Condition(s) or Problem(s) studied

Parkinson's Disease

Intervention(s)

A:levodopa;

Primary Outcome(s)

Genotype;

Source(s) of Monetary Support

National Natural Science Foundation of China